Bio Platforms

PEPTIDE DELIVERY – The Endometriosis Enigma – Why Can’t There Be a Pill for That?

Joel Tune, MBA, says for those peptide therapeutics that meet the necessary criteria, advances in formulation technologies coupled with favorable market dynamics will continue to drive interest across the entire prescription drug spectrum for safe and effective orally administered peptide therapeutics.

MONOCLONAL ANTIBODIES – The Development of Therapeutic Monoclonal Antibody Products: A Comprehensive Guide to CMC Activities From Clone to Clinic

Howard L. Levine, PhD, and Brendan R. Cooney, provide a guide to product development companies, service providers, investors, and analyst as they work their way through the complex and rapidly evolving world of therapeutic monoclonal antibodies.



Fusion Pharmaceuticals Announces $105-Million Financing

Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, recently announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed.


Autolus Therapeutics Unveils Next-Generation Technology & Pipeline

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the treatment of cancer, recently presented insights into the science behind tumor defense mechanisms and the company’s novel programmed T cell therapy programs in development.